CC-1065 analogs having two CPI subunits
    44.
    发明授权
    CC-1065 analogs having two CPI subunits 失效
    具有两个CPI亚基的CC-1065类似物

    公开(公告)号:US5541339A

    公开(公告)日:1996-07-30

    申请号:US659415

    申请日:1991-03-08

    CPC分类号: C07D519/00

    摘要: This invention concerns chemical compounds of general Formula ICPI.sub.1 -R.sub.5 -T-R'.sub.5 -CPI.sub.2 IThe compounds of Formula I are useful as uv light absorbers, antibacterial agents, and are particularly useful as antitumor agents. Representative compounds of Formula I have been shown to possess useful ranges of antitumor activity in standard laboratory animal tests.

    摘要翻译: PCT No.PCT / US89 / 03329 Sec。 371日期1991年3月8日 102(e)1991年3月8日PCT PCT 1989年8月7日PCT公布。 出版物WO90 / 02746 日本1990年3月22日本发明涉及通式Ⅸi-R5-T-R'5-CPI2I的化合物。式Ⅰ化合物可用作紫外光吸收剂,抗菌剂,特别可用作抗肿瘤剂。 式I的代表性化合物已被证明在标准实验室动物试验中具有有效的抗肿瘤活性范围。

    Bicyclic lactones
    47.
    发明授权
    Bicyclic lactones 失效
    双环内酯

    公开(公告)号:US4242268A

    公开(公告)日:1980-12-30

    申请号:US96645

    申请日:1979-11-23

    申请人: Robert C. Kelly

    发明人: Robert C. Kelly

    摘要: Process for preparing bicyclic lactone acrylic aldehydes and ketones of the formula ##STR1## wherein "n" is one or 2, wherein R.sub.1 is hydrogen, methyl, or ethyl, and wherein R.sub.4 is hydrogen or a blocking group; and those aldehydes, ketones, and intermediates prepared therein. The aldehydes and ketones are useful intermediates in preparing prostaglandins and analogs having pharmacological utility.

    摘要翻译: 制备式“IMAGE”的双环内酯丙烯酸醛和酮的方法,其中“n”是1或2,其中R 1是氢,甲基或乙基,并且其中R 4是氢或封闭基团; 和其中制备的醛,酮和中间体。 醛和酮是制备具有药理学效用的前列腺素和类似物的有用中间体。

    Enlarged-hetero-ring prostacyclin analogs with 5-halo feature
    48.
    发明授权
    Enlarged-hetero-ring prostacyclin analogs with 5-halo feature 失效
    具有5-卤素特征的扩增异环前列环素类似物

    公开(公告)号:US4215214A

    公开(公告)日:1980-07-29

    申请号:US935300

    申请日:1978-08-21

    申请人: Robert C. Kelly

    发明人: Robert C. Kelly

    摘要: Prostaglandin (PG.sub.1) derivatives having (1) a 6-keto feature, together with a 9-deoxy-9-hydroxymethyl feature for example ##STR1## or (2) a 9-deoxy-6,9-epoxymethano feature together with a 5-halo or 6-hydroxy feature, for example ##STR2## or a 5,6-didehydro feature, for example in an enol ether of the formula ##STR3## said derivatives having pharmacological activity. Processes for preparing them and the appropriate intermediates are disclosed.

    摘要翻译: 前体前列腺素(PG1)衍生物具有(1)6-酮特征,以及9-脱氧-9-羟甲基特征,例如(IMAGE)或(2)9-脱氧-6,9-环氧甲烷特征以及5 - 卤代或6-羟基特征,例如或5,6-脱水特征,例如在式(I)的烯醇醚中,所述衍生物具有药理活性。 公开了制备它们的方法和合适的中间体。

    9-Deoxy-6,9.alpha.-epoxymethano-PG C-1 alcohols
    49.
    发明授权
    9-Deoxy-6,9.alpha.-epoxymethano-PG C-1 alcohols 失效
    9-脱氧-6,9α-环氧甲烷-PG C-1醇

    公开(公告)号:US4206303A

    公开(公告)日:1980-06-03

    申请号:US940921

    申请日:1978-09-11

    申请人: Robert C. Kelly

    发明人: Robert C. Kelly

    CPC分类号: C07C405/0041 C07D311/94

    摘要: Processes for preparing prostacyclin analogs which are 9-deoxy-6,9-epoxymethano derivatives of prostaglandin F.sub.1.alpha. -type compounds, illustrated, for example, by a compound of the formula ##STR1## wherein .about. indicates alpha or beta configuration; including the products and intermediates produced therein, said products having pharmacological utility.

    摘要翻译: 制备作为前列腺素F1α型化合物的9-脱氧-6,9-环氧甲烷衍生物的前列环素类似物的方法,例如由下式表示的化合物,其中DIFFERENCE表示α或β构型; 包括其中生产的产品和中间体,所述产品具有药理实用性。

    Enlarged-hetero-ring prostacyclin analogs
    50.
    发明授权
    Enlarged-hetero-ring prostacyclin analogs 失效
    放大杂环前列环素类似物

    公开(公告)号:US4202971A

    公开(公告)日:1980-05-13

    申请号:US12263

    申请日:1979-02-15

    申请人: Robert C. Kelly

    发明人: Robert C. Kelly

    IPC分类号: C07C405/00 C07D311/94

    摘要: Prostaglandin (PG.sub.1) derivatives having (1) a 6-keto feature, together with a 9-deoxy-9-hydroxymethyl feature for example ##STR1## or (2) a 9-deoxy-6,9-epoxymethano feature together with a 5-halo or 6-hydroxy feature, for example ##STR2## or a 5,6-didehydro feature, for example in an enol ether of the formula ##STR3## said derivatives having pharmacological activity. Processes for preparing them and the appropriate intermediates are disclosed.

    摘要翻译: 前体前列腺素(PG1)衍生物具有(1)6-酮特征,以及9-脱氧-9-羟甲基特征,例如(IMAGE)或(2)9-脱氧-6,9-环氧甲烷特征以及5 - 卤代或6-羟基特征,例如 或5,6-二脱水特征,例如在式(I)的烯醇醚中,所述衍生物具有药理学活性。 公开了制备它们的方法和合适的中间体。